OSI-774/Cisplatin/Taxotere in Head & Neck Squamous Cell Cancer
- Conditions
- Interventions
- First Posted Date
- 2004-01-21
- Last Posted Date
- 2024-07-05
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 50
- Registration Number
- NCT00076310
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
Natrecor in Pulmonary Hypertension
- Conditions
- Interventions
- First Posted Date
- 2004-01-06
- Last Posted Date
- 2018-11-07
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 15
- Registration Number
- NCT00075179
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
Phase I/II Study of Decitabine and Valproic Acid in Relapsed/Refractory Leukemia or Myelodysplastic Syndromes
- Conditions
- Interventions
- First Posted Date
- 2003-12-31
- Last Posted Date
- 2018-11-15
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 54
- Registration Number
- NCT00075010
- Locations
- 🇺🇸
M.D. Anderson Cancer Center, Houston, Texas, United States
Comparing Fresh Random Platelets and Autologous Cryopreserved Thrombosol Treated Autologous Platelets
- First Posted Date
- 2003-12-23
- Last Posted Date
- 2012-08-02
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 4
- Registration Number
- NCT00074763
- Locations
- 🇺🇸
UT M.D. Anderson Cancer Center, Houston, Texas, United States
Study of DT388GMCSF Fusion Protein in Acute Myelogenous Leukemia (AML) and Chronic Myelomonocytic Leukemia (CMML)
- Conditions
- Interventions
- First Posted Date
- 2003-12-23
- Last Posted Date
- 2012-02-22
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 7
- Registration Number
- NCT00074750
- Locations
- 🇺🇸
The University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States
Filgrastim Plus Chemotherapy Compared With Filgrastim Alone In Treating Women Undergoing Peripheral Stem Cell Transplantation For Breast Cancer
- First Posted Date
- 2003-11-24
- Last Posted Date
- 2018-11-06
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 184
- Registration Number
- NCT00002836
- Locations
- 🇺🇸
University of Texas - MD Anderson Cancer Center, Houston, Texas, United States
Campath-1H Plus Rituximab for CD52- and CD20- Positive Refractory or Relapsed Chronic Lymphoid Disorders
- First Posted Date
- 2003-10-22
- Last Posted Date
- 2012-08-07
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 48
- Registration Number
- NCT00071396
- Locations
- 🇺🇸
University of Texas - MD Anderson Cancer Center, Houston, Texas, United States
Alopecia Areata Registry
- Conditions
- First Posted Date
- 2003-09-30
- Last Posted Date
- 2019-05-14
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 3100
- Registration Number
- NCT00069589
- Locations
- 🇺🇸
Columbia University, New York, New York, United States
🇺🇸University of California, San Francisco, San Francisco, California, United States
🇺🇸University of Colorado - UCHSC - Health Science Center at Fitzsimons, Aurora, Colorado, United States
Irinotecan in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma
- Conditions
- First Posted Date
- 2003-09-24
- Last Posted Date
- 2018-11-15
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 50
- Registration Number
- NCT00003245
- Locations
- 🇺🇸
University of Texas - MD Anderson Cancer Center, Houston, Texas, United States
Chemotherapy, Interferon Alfa, and Radiation Therapy in Treating Patients Who Have Undergone Surgery For Pancreatic Cancer
- Conditions
- Interventions
- First Posted Date
- 2003-09-11
- Last Posted Date
- 2012-02-15
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 29
- Registration Number
- NCT00068575
- Locations
- 🇺🇸
M. D. Anderson Cancer Center at University of Texas, Houston, Texas, United States